Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.

Annals of surgical oncology - 1 Sept 2017

Zern Nicole K, Clifton-Bligh Roderick, Gill Anthony J, Aniss Ahmad, Sidhu Stan, Delbridge Leigh, Learoyd Diana, Robinson Bruce, Sywak Mark

Abstract excerpt

BACKGROUND: Dynamic risk stratification is utilized in the follow-up of patients with papillary thyroid carcinoma (PTC). Analysis of outcomes after biochemical incomplete response (BIR) to initial therapy will allow better individualization of care. METHODS: A total of 494 patients with PTC were followed prospectively. Immunohistochemistry (IHC) for BRAFV600E mutation was completed on all surgical specimens....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Vessels
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Radiotherapy, Adjuvant

Share to Thyroglobulin

Share to Thyroid Neoplasms

Share to Thyroidectomy

Share to Thyrotropin

Source

Identifiers

PMID: 28585075
DOI: 10.1245/s10434-017-5911-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.PMID 28585075Read ↗

Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response.Semantic proximity Read ↗

BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.Semantic proximity Read ↗

Response to therapy of papillary thyroid cancer of known BRAF status.Semantic proximity Read ↗

Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid CancerSemantic proximity Read ↗

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Semantic proximity Read ↗

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerSemantic proximity Read ↗

The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study.Semantic proximity Read ↗

Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid CancerSemantic proximity Read ↗

The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years OldSemantic proximity Read ↗

A predictive nomogram for progression-free survival in radioiodine-refractory papillary thyroid carcinoma after reoperation: a longitudinal study in Vietnam.Semantic proximity Read ↗

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaSemantic proximity Read ↗

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.